We report three cases of post-transplant lymphoproliferative disorder (PTLD) in the context of autologous stem cell transplantation (ASCT) for multiple myeloma (MM) and non-Hodgkin's lymphoma. The first two cases received ASCT for MM, one with a CD34-selected autograft and the other with an unmanipulated autograft. Both these cases of PTLD achieved a complete response following treatment with IVIG, gancyclovir, solumedrol and interferon (IFN). The third case received ASCT with an unmanipulated autograft for relapsed angioimmunoblastic lymphoma. He also achieved a complete response but only after rituximab was added to IVIG, gancyclovir, solumedrol and IFN. None of these patients experienced a relapse of their PTLD with follow-up ranging from 1.5 to 5 years. These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT. They also demonstrate the possibility of durable complete remission of post-ASCT PTLD following antiviral and immune modulating therapy.
limited disease. 1, 2 The data for other treatment modalities are largely anecdotal.
In autologous stem cell transplantation (ASCT), only rare cases have been reported, most of which have recently been summarized by Lones and colleagues. 3 These previously reported patients received ASCT for chronic myelogenous leukemia, T cell acute lymphoblastic leukemia, Hodgkin's disease, non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and neuroblastoma. Outcomes in general were poor, and the only successful treatments for PTLD were seen in two patients who received interferon (IFN). 4, 5 We report three cases of PTLD occurring after ASCT for MM and NHL, who were successfully managed with antiviral and immunomodulating therapy.
Case reports

Case 1
A 41-year-old man was diagnosed with a stage IIA IgG kappa MM in April 1996. He was treated with two cycles of VAD (vincristine 0.4 mg i.v. daily ϫ 4, adriamycin 9 mg/m 2 i.v. daily ϫ 4, and dexamethasone 40 mg p.o. on days 1-4, 9-12 and 17-20) . He then underwent stem cell mobilization with dose-intensive cyclophosphamide 5.25 g/m 2 i.v., etoposide 1 g/m 2 i.v., cisplatin 100 mg/m 2 i.v. (DICEP) and s.c. G-CSF, as previously reported. 6 This was uncomplicated except for culture-negative febrile neutropenia. Four months after initial diagnosis he received highdose melphalan 180 mg/m 2 and 500 cGy TBI (Me/TBI) followed by CD34-selected (CellPro CEPRATE SC System, Bothell, WA, USA) ASCT with 9.68 ϫ 10 6 CD34 ϩ cells/kg. His early post-ASCT course was complicated by mucositis and culture-negative febrile neutropenia. Engraftment of neutrophils Ͼ0.5 ϫ 10 9 /l occurred on day ϩ12 and platelets Ͼ20 ϫ 10 9 /l occurred on day ϩ13 post ASCT. Following both DICEP and Me/TBI he received prophylactic trimethoprim-sulfamethoxazole, ciprofloxacin, acyclovir and mycostatin.
He returned to hospital on day ϩ31 post ASCT with fever, malaise and a dermatomal herpes simplex infection of the thigh and penis. He was treated with acyclovir 5 mg/kg i.v. three times per day. A few days later he was found to have a cytomegalovirus (CMV) infection in the urine, and the acyclovir was changed to gancyclovir 5 mg/kg i.v. twice daily for 2 weeks. He also received two doses of intravenous immune globulin (IVIG) 1 g/kg. He subsequently developed a hospital-acquired pneumonia and a mild hemolytic anemia. A course of cefuroxime and gentamicin was started. He was also treated with prednisone 60 mg daily for his hemolytic anemia on day ϩ50.
He recovered well and was discharged home but was readmitted with rhinitis, pharnygitis, fever, severe nausea and vomiting, and small soft submandibular, cervical and inguinal lymph nodes. His lymphadenopathy grew rapidly in the head and neck region. He was intubated for impending airway obstruction on day ϩ63 and was admitted to the ICU for 5 days. An inguinal lymph node biopsy confirmed the diagnosis of polymorphous PTLD. His Epstein-Barr virus (EBV) serology was positive for IgG but negative for IgM. He was treated with solumedrol 40 mg i.v. twice daily, 30 g IVIG daily ϫ 1 week, gancyclovir 5 mg/kg i.v. twice daily ϫ 3 weeks, and IFN alpha 2b 3 million units s.c. daily. His lymphadenopathy diminished rapidly in 2 days and resolved completely over 3 weeks. He was discharged home on prednisone 20 mg p.o. daily, IFN alpha 2b 3 MU s.c. three times per week, and trimethoprim-sulphamethoxazole for Pneumocystis carinii pneumonia (PCP) prophylaxis. He slowly tapered the prednisone over 7 weeks and remained on INF for 6 months.
The patient currently remains in remission from his PTLD, now 5 years after his diagnosis. His MM is stable with a monoclonal IgG kappa of 11 g/l and a normal CBC. He has suffered from frequent episodes of communityacquired pneumonia since his transplant.
Case 2
In September 1998, a 50-year-old Caucasian man with a recent history of recurrent pneumonia, was diagnosed with stage IA IgG lambda MM. He was treated with four cycles of VAD and then DICEP plus G-CSF for stem cell mobilization. In December 1998, he received Me/TBI and ASCT as per case No. 1 except that his autograft was not manipulated by CD34 ϩ selection. At the time of ASCT he received 6 ϫ 10 6 CD34 ϩ cells/kg. Stem cell mobilization and highdose chemotherapy were also complicated by culture-negative febrile neutropenia. Engraftment occurred on day ϩ13 post ASCT. He sustained a grade II mucositis and transient renal insufficiency with a peak serum creatinine of 142 mol/l.
He was readmitted to hospital on day ϩ45 post ASCT with fever, chills, lethargy, myalgias, splenomegaly and cervical lymphadenopathy. His lymphadenopathy rapidly enlarged over the subsequent 3 days, and spread to his axilla, neck, spleen and inguinal region. He was started on ciprofloxacin, clindamycin, piperacillin-tazobactam, and full-dose trimethoprim-sulphamathoxazole, with no response.
An inguinal lymph node biopsy confirmed polymorphous PTLD. EBV IgM was negative while the IgG was positive. He began treatment with solumedrol, gancyclovir, IVIG, IFN alpha 2b as described for case No. 1. His symptoms rapidly resolved as did his lymphadenopathy and fever. He left hospital on IFN alpha 2b 3 MU s.c. 3 ϫ per week, tapering doses of prednisone, and trimethoprim-sulphamethoxazole for PCP prophylaxis. The patient continued IFN treatment at 2 MU s.c.3 ϫ per week for 14 months. He experienced recurrent sinusitis and bronchitis post ASCT and was hospitalized approximately 1 year post ASCT for pneumonia. He then received 6 months of suppressive antibiotic treatment with biaxin and has not had further infections. He is currently more than 3 years post ASCT and remains in remission from both his MM and PTLD.
Case 3
A 38-year-old man was diagnosed with stage IIIB, T cell angioimmunoblastic lymphoma in 1994. He entered CR with six cycles of CHOP. His chemotherapy was complicated by an episode of PCP. Four years later he developed idiopathic thrombocytopenic purpura (ITP) and was treated with a course of steroids and IVIG.
Six years after his initial diagnosis, he had biopsy-proven lymphoma relapse in the inguinal region and spleen. He was given salvage chemotherapy with DICEP and developed group C streptococcal bacteremia while neutropenic. Eight weeks later, in August 2000, he received myeloablative therapy with our standard high-dose regimen for 'low grade' lymphoma consisting of fludarabine 50 mg/m 2 i.v. daily for 5 days, and busulfan 3.2 mg/kg i.v. daily for 4 days. He received 19 ϫ 10 6 CD34 ϩ cells/kg and his platelets engrafted on day ϩ10 and neutrophils on day ϩ11. He received prophylactic mycostatin, acyclovir and ciprofloxacin as did the previous two cases, but required atovoquone for PCP prophylaxis because of a severe sulfa drug allergy. His course was complicated by culture-negative febrile neutropenia and grade 1 mucositis. His Hb was 156 ϫ 10 9 /l and platelets 121 g/l on day ϩ19 post ASCT.
The patient then presented on day ϩ46 post-transplant with a 2-3 week history of malaise, low-grade fevers, nausea, vomiting, pancytopenia, progressive lymphadenopathy of the cervical and supraclavicular region, and massive splenomegaly extending 12 cm below the costal margin. His initial blood work included a Hb of 64 g/l, WBC 0.5 ϫ 10 9 /l, platelets 24 ϫ 10 9 /l, ANC 0.2 ϫ 10 9 /l, LDH 469 U/l, alkaline phosphatase 143 U/l, bilirubin 33 mol/l, and a normal ALT. A CT scan of the chest and abdomen revealed mediastinal and periportal lymphadenopathy, and mild hepatomegaly. He was initially treated with ceftazidime and gancyclovir. A bone marrow biopsy was negative for lymphoma and demonstrated adequate megakaryocytes suggesting a variant of ITP. There was no evidence of hemophagocytosis in the marrow. At this point steroids were initiated.
A cervical lymph node biopsy 5 days later revealed a B cell PTLD. The tissue was also strongly positive for EBV DNA. His EBV serology was IgG positive and IgM negative, and he was newly IgG positive for parvovirus. All other cultures and viral serologies were negative. He was then treated as the previous two cases with gancyclovir, IVIG and IFN. He became afebrile and stabilized but there was no appreciable tumor response to this regimen. Rituxi-mab 375 mg/m 2 i.v. weekly for 8 weeks was added on day ϩ62. The patient slowly responded over 10 weeks. Further complications included splenic infarcts as well as an episode of PCP on day ϩ71 due to non-compliance with prophylaxis. He also suffered from rapidly progressive Staphlococcus aureus lymphadenitis of the head and neck region approximately 10 months post transplantation, requiring prophylactic intubation, incision and drainage and prolonged antibiotics.
Unfortunately, he developed recurrent cervical lymphadenopathy 14 months post ASCT. This was biopsied and proven to be another relapse of his original T cell angioimmunoblastic lymphoma. At present he is physically well and most of his recurrent lymphadenopathy spontaneously regressed without any therapy. He has no evidence of recurrent PTLD now 23 months post ASCT.
Pathological findings
All three cases showed similar histological features and will therefore be described together. Complete effacement of the normal lymph node architecture by a diffuse proliferation of hematolymphoid cells was seen. Focal necrosis and hemorrhage was present. The lymphoid population was heterogeneous, and included small cleaved lymphocytes, plasma cells and numerous immunoblasts, some of which appeared atypical (Figure 1 ). The mitotic rate was high, and apoptotic bodies were easily identified.
Immunohistochemical staining revealed the majority of the large immunoblastic cells to be of B cell origin (CD20 and IgG positive). In case 1, a striking predominance of cytoplasmic lambda light chains was apparent in the immunoblasts, with a corresponding lack of staining for kappa light chains (Figure 2) .
Using standard polymerase chain reaction (PCR) methodology, the EBV genome was strongly amplified in all cases. Figure 3 illustrates the results for cases 1 and 2. Figure 1 Complete effacement of the lymph node architecture by a polymorphous lymphoid infiltrate is seen (hematoxylin and eosin (H&E): original magnification ϫ40).
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Additionally, a strong immunoglobulin heavy chain (IgH) rearrangement was found in these cases, using PCR. Weaker, but definite T cell receptor (TCR) gamma rearrangements were also noted. The arrangements from case 1 are shown in Figure 4 .
The pathological findings in all cases were those of EBVassociated PTLDs of the polymorphic type. Evidence of B cell clonality was present.
Discussion
Despite over 20 years of experience with autologous blood and bone marrow transplantation, very few cases of PTLD have been reported. 3 This is not surprising considering the fact that the incidence of PTLD after allogeneic BMT is Ͻ1% and ASCT is less immunosuppressive than allogeneic BMT. 2 Risk factors have not been defined for ASCT, but authors have speculated on the role of T cell depleting the autograft, concurrent CMV infection, and impaired cytolytic T cell response specifically to EBV. 3, 7 In the autologous bone marrow patients with PTLD reported previously, three were in the context of T cell-depleted grafts, and one in a B celldepleted graft. 4, [8] [9] [10] One patient was also on prednisone as part of his treatment for PCP and CMV pneumonitis. 11 In our case reports, two had MM which is associated with defective humoral immunity, and the case of angioimmunoblastic NHL is associated with defective cell-mediated immunity. All three patients had stem cells mobilized with DICEP. This intensive immunosuppressive regimen may have played a role in the development of PTLD. In total we have treated 185 patients with DICEP as well as 417 patients with ASCT from 1995 to 2001, and we have only identified three cases of PTLD. It is of interest that all three patients had recurrent infections post ASCT and two of the three had recurrent infections pre-ASCT.
PTLD is thought to be related to a high degree of immunosuppression allowing unregulated proliferation of EBV transformed B lymphocytes. 1 While most cases are EBV related, there is a small subset of patients with T cell lymphomas that are EBV negative. 12 In our patients, PCR confirmed the presence of EBV genome. The positive IgG and negative IgM serology for EBV in these cases suggests reactivation of latent infection. Clonality was confirmed by immunohistochemical stains that demonstrated immunoglobulin light chain restriction as well as by PCR that demonstrated IgH gene rearrangement and TCR gene rearrangement. The significance of the TCR gene rearrangement is not clear, however, it has been well reported. 8, 13 Perhaps the presence of both IgH and TCR gene rearrangements indicate oligoclonality, and therefore a better prognosis than monoclonal changes. In our patients, the early presentation of PTLD post ASCT may partially explain the favorable response to therapy. 1, 6 In PTLD, EBV causes a spectrum of changes ranging from hyperplasia to frank malignancy. Three categories are now recognized: plasmacytic hyperplasia, polymorphous PTLD and monomorphic PTLD/malignant lymphoma/myelomas. 1 This classification has proved useful as it helps predict response to therapy. In the hyperplasia group, tumors will often regress with reduction of immunosuppression, whereas monomorphic PTLDs tend to be refractory to therapy. Our three patients fall into the polymorphic category, where one may expect a more favorable response to therapy. In the previous patients reported, three patients had a polyclonal PTLD, but only one survived. This surviving patient was treated similarly to our patients with methylprednisolone, acyclovir and IFN. 5 When PTLD occurs after ASCT, treatment options include antivirals, lymphocytotoxic therapy or immune modulation. In EBV infected cells, gancyclovir has been shown to be superior to acyclovir.
14 Gancyclovir is likely to be effective only with early lytic EBV infection and probably will not alter the replication of latently infected B cells.
14 Unfortunately, data on gancyclovir in PTLD are limited, but remission was achieved in one of two patients treated in the solid organ transplant setting. 15 It is difficult to assess the individual contribution of gancyclovir in our patients; however, two patients attained a complete response (CR) in the presence of this drug. There are three previously reported patients treated with gancyclovir in the post-ASCT setting, all of whom died of their disease. 3, 11, 16 IVIG has not been tried as single agent therapy for PTLD. Because most MM patients are hypogammaglobulinemic, inclusion of this agent would seem reasonable. IVIG was used in two of the seven previously reported cases of PTLD after ASCT. In the first case, it was given in conjunction with IFN and acyclovir. 4 The patient had a CR, but died of CMV pneumonitis. In the second case, IVIG was given in combination with septra, gancyclovir and prednisone. 11 The patient died of PTLD. Steroids have proven benefit in lymphoma. The effect is related both to decreasing edema and to a direct cytotoxic effect on the tumor cells. Three of the seven reported cases of PTLD after ASCT were treated with corticosteroids and the only patient who survived also had therapy with acyclovir and IFN. 5, 8, 11 IFN has been shown to reduce EBV-induced B cell proliferation, and has been successfully used in other hematologic malignancies. 17 Shapiro et al 18 reported the first cases of IFN for B cell lymphoproliferative disorders (two post BMT), with dramatic responses to IFN and IVIG. 18 O'Brien et al 19 reviewed 13 cases of PTLD treated with IFN, and favorable responses were seen in those with limited disease, and polyclonal tumors. In a recent prospective trial of a step-wise approach to PTLD in solid organ transplant recipients, a 50% CR rate was observed with IFN therapy. 20 It was generally well tolerated. However, two patients developed de novo PTLDs on IFN treatment. In the nine previously reported cases in ASCT, the two cases that responded to treatment were also given IFN. 4 ,5 Duration of treatment is not known, but IFN remains an attractive alternative to chemotherapy to avoid further immunosuppression through cytotoxic therapy. In two of our patients, it was also continued for maintenance therapy in MM. Interestingly, IFN has been shown to correct abnormal TCR rearrangement in hairy cell leukemia 21 and in chronic active EBV infection. 13 The effect of IFN on the molecular changes in our patients is not known.
Anti-B cell monoclonal antibodies have shown promising results in patients with oligoclonal PTLDs. In a subgroup of BMT patients, nine of 10 patients with oligoclonal PTLD achieved a CR with anti-CD21/24 antibodies. 22 A recent retrospective analysis of solid organ and BMT patients using rituximab showed a 54% CR rate, and a 69% PR rate to rituximab in 32 patients. 23 Another report is of three patients post-allogeneic BMT who received rituximab for PTLD in two patients and rising EBV virus DNA levels in the other patient. 24 The two PTLD patients received rituximab alone. However, the third also received corticosteroids and cytotoxic T lymphocytes active against EBV. All three patients had a CR and reduction of EBV DNA levels to normal. In our patient with limited bone marrow reserve, rituximab offers an alternative to more myelosuppressive treatments. Long-term implications of B cell deficiency secondary to rituximab are unknown. This is of Bone Marrow Transplantation particular concern with post-BMT patients who are already immunosuppressed. PTLD is a rare but potentially fatal complication of bone marrow transplantation. 2 For this reason, and because PTLD can mimic recurrent disease for which patients may receive ASCT, it is important to keep this on the differential of post-ASCT lymphadenopathy and unexplained fever. There is no standard treatment for PTLD following ASCT, but our three cases demonstrate encouraging results with a combination of corticosteroids, IVIG, gancyclovir, and IFN, ϩ/Ϫ rituximab in a disease that is often refractory to any treatment.
